美股异动丨诺华制药盘前涨近2%，布局过敏性疾病新靶点

Core Insights - Novartis (NVS.US) shares rose nearly 2% pre-market, reaching $132.73 [1] - Novartis has entered into a deal worth over $1.7 billion with UK biotech company Relation Therapeutics to identify drug targets for allergic diseases [1] - The collaboration aims to combine Novartis's expertise in immunodermatology with Relation's AI-driven drug discovery platform, which utilizes patient data, including human tissue, to uncover the genetic basis of disease manifestations [1]